Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.
Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.
Penumbra, Inc. (NYSE: PEN) has announced a conference call scheduled for August 3, 2020, at 4:30 PM ET to discuss its financial results for the second quarter of 2020. A press release detailing the financial results will be issued after market close on the same day. The conference call can be accessed by phone or via webcast on the company’s website. Penumbra is a global healthcare company focused on innovative therapies and sells its products to hospitals and healthcare providers primarily through a direct sales organization.